- BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating.
- The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy.
- Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
- Though the analyst expects a gradual increase in sales due to manufacturing limitations, in the long term, he sees a blockbuster opportunity for Carvykti as the leader in multiple myeloma CAR T therapies with peak sales of around $5.5 billion.
- Legend and its collaborator Janssen, a unit of Johnson & Johnson (NYSE:JNJ), are working on expanding Carvykti's addressable population through approvals in earlier lines and Japan & China that will bolster additional growth.
- The analyst also notes upcoming data readouts from earlier-line therapies that can drive short-term upside.
- Price Action: LEGN shares are up 6.84% at $45.90 during the market session on the last check Friday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Legend Biotech Shares Move Higher After Bullish BMO Pitch
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks